Cannabinoids for Parkinson's and Dementia in Older Adults: Promising Biology, Almost No Clinical Proof

This review confronted a growing clinical reality: older adults with Parkinson's disease and dementia are increasingly using cannabinoids, but the evidence supporting this use is almost entirely preclinical. In the lab, CBD showed anti-amyloidogenic (reduces Alzheimer's-associated protein buildup), antioxidative, anti-apoptotic, anti-inflammatory, and neuroprotective effects. THC also showed neuroprotective properties in some models.

In clinical practice, patients were using cannabis for Parkinson's tremor, non-motor symptoms, anxiety, and sleep. For dementia, cannabis was being used to manage agitation and other responsive behaviors. Some clinicians considered cannabinoids an alternative when first-line treatments failed.

But the review was explicit: strong evidence from clinical trials was scarce for most indications. The gap between preclinical promise and clinical proof was wide. And age-related changes in the endocannabinoid system could alter how older adults respond to cannabinoids in ways that haven't been studied.

The population most likely to have neurodegenerative disease — older adults — is also the population most vulnerable to drug interactions and side effects, and the population least represented in cannabis research. This review highlighted a troubling pattern: patients and some clinicians were already treating Parkinson's and dementia with cannabis based on preclinical data and anecdotal reports, while the clinical trials that would confirm or refute benefit barely existed.

The age-related ECS changes add another concern. If the endocannabinoid system functions differently in a 75-year-old brain compared to a 25-year-old brain (as limited evidence suggests), dosing and effects could be unpredictable in exactly the population using it.